Ken Griffin’s Bioventus BVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$156K Sell
17,085
-43,840
-72% -$368K ﹤0.01% 11648
2025
Q4
$453K Buy
+60,925
New +$438K ﹤0.01% 9265
2025
Q3
Sell
-34,932
Closed -$242K 12836
2025
Q2
$231K Sell
34,932
-28,085
-45% -$199K ﹤0.01% 10388
2025
Q1
$577K Buy
63,017
+46,287
+277% +$462K ﹤0.01% 8168
2024
Q4
$176K Sell
16,730
-252,040
-94% -$2.98M ﹤0.01% 10651
2024
Q3
$3.21M Sell
268,770
-273,993
-50% -$2.37M ﹤0.01% 4677
2024
Q2
$3.12M Buy
542,763
+431,433
+388% +$2.37M ﹤0.01% 4515
2024
Q1
$579K Buy
111,330
+33,725
+43% +$165K ﹤0.01% 8058
2023
Q4
$409K Buy
77,605
+77,601
+1,940,025% +$307K ﹤0.01% 8521
2023
Q3
$13 Sell
4
-20,720
-100% -$72.7K ﹤0.01% 14197
2023
Q2
$59.9K Buy
+20,724
New +$39.8K ﹤0.01% 11590
2023
Q1
Sell
-39,023
Closed -$102K 14751
2022
Q4
$102K Sell
39,023
-41,921
-52% -$183K ﹤0.01% 11193
2022
Q3
$567K Sell
80,944
-58,221
-42% -$456K ﹤0.01% 8183
2022
Q2
$950K Buy
139,165
+77,043
+124% +$786K ﹤0.01% 7136
2022
Q1
$876K Buy
62,122
+36,567
+143% +$489K ﹤0.01% 8004
2021
Q4
$370K Buy
25,555
+9,650
+61% +$137K ﹤0.01% 10434
2021
Q3
$226K Sell
15,905
-6,880
-30% -$106K ﹤0.01% 11708
2021
Q2
$401K Buy
+22,785
New +$367K ﹤0.01% 10550

Other funds holding BVS

Ken Griffin's BVS Position: Q1 2026 in Review

Ken Griffin reduced its Bioventus (BVS) stake by 72% in Q1 2026, selling an estimated $368K and leaving 17,085 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #11648.

Ken Griffin first reported a position in BVS in Q2 2021 and has held it in 18 quarters since. The position peaked at $3.21M in Q3 2024. 157 funds tracked by Wall St. Rank hold BVS as of Q1 2026.

  • Ken Griffin held 17,085 shares of Bioventus worth $156K as of Q1 2026.
  • Ken Griffin sold 43,840 Bioventus shares in Q1 2026, an estimated $368K.
  • Bioventus made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #11648 holding.
  • Ken Griffin first reported a position in Bioventus in Q2 2021 and has held it in 18 quarters since.
  • Ken Griffin's Bioventus position peaked at $3.21M in Q3 2024.
  • 157 funds tracked by Wall St. Rank held Bioventus as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.